Agilent Technologies, Inc. (A) EV/Assets Ratio: 2.98x
Is Agilent Technologies, Inc.’s EV/Assets ratio high or low?
Agilent Technologies, Inc.'s EV/Assets ratio of 2.98x is 20% below its 5-year average of 3.71x, near the low end of its 5-year range (2.55x–5.37x).
The EV/Assets ratio for Agilent Technologies, Inc. (A) is 2.98x as of Wednesday, June 10, 2026. It is below its 12-month average by 2.54% (3.06x).
A EV/Assets Ratio Chart
A Average EV/Assets Ratio Chart
A Current vs Average EV/Assets Ratio Chart
A EV/Assets Ratio Metrics
EV/ASSETS RATIO
2.98x
EV/ASSETS RATIO AVG TTM
3.06x
EV/ASSETS RATIO AVG 3Y
3.38x
EV/ASSETS RATIO AVG 5Y
3.71x
EV/ASSETS RATIO AVG 10Y
3.22x
EV/ASSETS RATIO AVG 15Y
2.57x
EV/ASSETS RATIO AVG 20Y
2.21x
CURRENT VS TTM AVG
-2.54%
CURRENT VS 3Y AVG
-11.89%
CURRENT VS 5Y AVG
-19.72%
CURRENT VS 10Y AVG
-7.32%
CURRENT VS 15Y AVG
+16.14%
CURRENT VS 20Y AVG
+34.70%
A Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | — | 2.98x | 3.06x | 3.38x | 3.71x |
| Zoetis Inc. (ZTS) | $34.20B | 2.75x | 4.26x | 5.44x | 5.84x |
| Centene Corporation (CNC) | $31.94B | 0.33x | 0.25x | 0.39x | 0.51x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 1.05x | 1.56x | 1.81x | 1.98x |
| Humana Inc. (HUM) | $43.78B | 0.96x | 0.75x | 0.88x | 1.10x |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 13.69x | 15.32x | 13.69x | 15.18x |
| DexCom, Inc. (DXCM) | $29.24B | 4.53x | 4.23x | 5.88x | 7.47x |
| Biogen Inc. (BIIB) | $29.00B | 1.10x | 0.95x | 1.19x | 1.43x |
| Veeva Systems Inc. (VEEV) | $27.37B | 2.85x | 4.64x | 5.33x | 7.00x |
| Waters Corporation (WAT) | $23.83B | 1.43x | 4.12x | 4.55x | 5.47x |
Agilent Technologies, Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Agilent Technologies, Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Agilent Technologies, Inc. (A)?
- The EV/Assets ratio for A stock is 2.98x.
- Is Agilent Technologies, Inc.'s EV/Assets ratio high or low?
- Agilent Technologies, Inc.'s EV/Assets ratio of 2.98x is 20% below its 5-year average of 3.71x, near the low end of its 5-year range (2.55x–5.37x).
- What is the TTM average EV/Assets ratio for Agilent Technologies, Inc. (A)?
- The TTM average EV/Assets ratio for A stock is 3.06x.
- What is the 3Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
- The 3Y average EV/Assets ratio for A stock is 3.38x.
- What is the 5Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
- The 5Y average EV/Assets ratio for A stock is 3.71x.
- What is the 10Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
- The 10Y average EV/Assets ratio for A stock is 3.22x.
- What is the 15Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
- The 15Y average EV/Assets ratio for A stock is 2.57x.
- What is the 20Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
- The 20Y average EV/Assets ratio for A stock is 2.21x.
Agilent Technologies, Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-10 | 2.98x |
| 2026-06-09 | 3.06x |
| 2026-06-08 | 3.00x |
| 2026-06-05 | 3.06x |
| 2026-06-04 | 3.13x |
| 2026-06-03 | 3.11x |
| 2026-06-02 | 3.05x |
| 2026-06-01 | 3.07x |
| 2026-05-29 | 3.13x |
| 2026-05-28 | 3.13x |
| 2026-05-27 | 2.69x |
| 2026-05-26 | 2.68x |
| 2026-05-22 | 2.67x |
| 2026-05-21 | 2.67x |
| 2026-05-20 | 2.65x |
| 2026-05-19 | 2.58x |
| 2026-05-18 | 2.61x |
| 2026-05-15 | 2.60x |
| 2026-05-14 | 2.63x |
| 2026-05-13 | 2.62x |
| 2026-05-12 | 2.63x |
| 2026-05-11 | 2.60x |
| 2026-05-08 | 2.69x |
| 2026-05-07 | 2.75x |
| 2026-05-06 | 2.73x |
| 2026-05-05 | 2.73x |
| 2026-05-04 | 2.61x |
| 2026-05-01 | 2.66x |
| 2026-04-30 | 2.69x |
| 2026-04-29 | 2.59x |
| 2026-04-28 | 2.67x |
| 2026-04-27 | 2.69x |
| 2026-04-24 | 2.69x |
| 2026-04-23 | 2.66x |
| 2026-04-22 | 2.79x |
| 2026-04-21 | 2.83x |
| 2026-04-20 | 2.81x |
| 2026-04-17 | 2.83x |
| 2026-04-16 | 2.75x |
| 2026-04-15 | 2.78x |
| 2026-04-14 | 2.79x |
| 2026-04-13 | 2.73x |
| 2026-04-10 | 2.67x |
| 2026-04-09 | 2.68x |
| 2026-04-08 | 2.72x |
| 2026-04-07 | 2.65x |
| 2026-04-06 | 2.67x |
| 2026-04-02 | 2.68x |
| 2026-04-01 | 2.66x |
| 2026-03-31 | 2.65x |
| 2026-03-30 | 2.61x |
| 2026-03-27 | 2.57x |
| 2026-03-26 | 2.64x |
| 2026-03-25 | 2.63x |
| 2026-03-24 | 2.66x |
| 2026-03-23 | 2.61x |
| 2026-03-20 | 2.59x |
| 2026-03-19 | 2.60x |
| 2026-03-18 | 2.60x |
| 2026-03-17 | 2.62x |
| 2026-03-16 | 2.60x |
| 2026-03-13 | 2.60x |
| 2026-03-12 | 2.60x |
| 2026-03-11 | 2.68x |
| 2026-03-10 | 2.68x |
| 2026-03-09 | 2.71x |
| 2026-03-06 | 2.68x |
| 2026-03-05 | 2.74x |
| 2026-03-04 | 2.80x |
| 2026-03-03 | 2.76x |
| 2026-03-02 | 2.76x |
| 2026-02-27 | 2.83x |
| 2026-02-26 | 2.82x |
| 2026-02-25 | 2.91x |
| 2026-02-24 | 2.90x |
| 2026-02-23 | 2.89x |
| 2026-02-20 | 2.87x |
| 2026-02-19 | 2.94x |
| 2026-02-18 | 2.96x |
| 2026-02-17 | 2.89x |
| 2026-02-13 | 2.93x |
| 2026-02-12 | 2.91x |
| 2026-02-11 | 3.00x |
| 2026-02-10 | 3.00x |
| 2026-02-09 | 2.97x |
| 2026-02-06 | 3.01x |
| 2026-02-05 | 3.02x |
| 2026-02-04 | 3.09x |
| 2026-02-03 | 3.07x |
| 2026-02-02 | 3.14x |
| 2026-01-30 | 3.11x |
| 2026-01-29 | 3.10x |
| 2026-01-28 | 3.11x |
| 2026-01-27 | 3.16x |
| 2026-01-26 | 3.15x |
| 2026-01-23 | 3.14x |
| 2026-01-22 | 3.22x |
| 2026-01-21 | 3.24x |
| 2026-01-20 | 3.15x |
| 2026-01-16 | 3.24x |
| 2026-01-15 | 3.35x |
| 2026-01-14 | 3.38x |
| 2026-01-13 | 3.39x |
| 2026-01-12 | 3.43x |
| 2026-01-09 | 3.44x |
| 2026-01-08 | 3.38x |
| 2026-01-07 | 3.42x |
| 2026-01-06 | 3.42x |
| 2026-01-05 | 3.31x |
| 2026-01-02 | 3.20x |
| 2025-12-31 | 3.16x |
| 2025-12-30 | 3.19x |
| 2025-12-29 | 3.20x |
| 2025-12-26 | 3.21x |
| 2025-12-24 | 3.21x |
| 2025-12-23 | 3.21x |
| 2025-12-22 | 3.21x |
| 2025-12-19 | 3.19x |
| 2025-12-18 | 3.34x |
| 2025-12-17 | 3.34x |
| 2025-12-16 | 3.40x |
| 2025-12-15 | 3.43x |
| 2025-12-12 | 3.41x |
| 2025-12-11 | 3.48x |
| 2025-12-10 | 3.50x |
| 2025-12-09 | 3.43x |
| 2025-12-08 | 3.47x |
| 2025-12-05 | 3.54x |
| 2025-12-04 | 3.61x |
| 2025-12-03 | 3.63x |
| 2025-12-02 | 3.62x |
| 2025-12-01 | 3.65x |
| 2025-11-28 | 3.73x |
| 2025-11-26 | 3.75x |
| 2025-11-25 | 3.82x |
| 2025-11-24 | 3.73x |
| 2025-11-21 | 3.68x |
| 2025-11-20 | 3.53x |
| 2025-11-19 | 3.52x |
| 2025-11-18 | 3.51x |
| 2025-11-17 | 3.52x |
| 2025-11-14 | 3.58x |
| 2025-11-13 | 3.58x |
| 2025-11-12 | 3.69x |
| 2025-11-11 | 3.64x |
| 2025-11-10 | 3.57x |
| 2025-11-07 | 3.57x |
| 2025-11-06 | 3.59x |
| 2025-11-05 | 3.57x |
| 2025-11-04 | 3.56x |
| 2025-11-03 | 3.53x |
| 2025-10-31 | 3.57x |
| 2025-10-30 | 3.50x |
| 2025-10-29 | 3.49x |
| 2025-10-28 | 3.55x |
| 2025-10-27 | 3.57x |
| 2025-10-24 | 3.60x |
| 2025-10-23 | 3.59x |
| 2025-10-22 | 3.55x |
| 2025-10-21 | 3.55x |
| 2025-10-20 | 3.49x |
| 2025-10-17 | 3.46x |
| 2025-10-16 | 3.44x |
| 2025-10-15 | 3.41x |
| 2025-10-14 | 3.37x |
| 2025-10-13 | 3.38x |
| 2025-10-10 | 3.34x |
| 2025-10-09 | 3.42x |
| 2025-10-08 | 3.44x |
| 2025-10-07 | 3.38x |
| 2025-10-06 | 3.45x |
| 2025-10-03 | 3.46x |
| 2025-10-02 | 3.39x |
| 2025-10-01 | 3.38x |
| 2025-09-30 | 3.15x |
| 2025-09-29 | 3.04x |
| 2025-09-26 | 3.03x |
| 2025-09-25 | 2.99x |
| 2025-09-24 | 3.05x |
| 2025-09-23 | 3.09x |
| 2025-09-22 | 3.10x |
| 2025-09-19 | 3.10x |
| 2025-09-18 | 3.13x |
| 2025-09-17 | 3.11x |
| 2025-09-16 | 3.12x |
| 2025-09-15 | 3.08x |
| 2025-09-12 | 3.03x |
| 2025-09-11 | 3.11x |
| 2025-09-10 | 3.05x |
| 2025-09-09 | 3.10x |
| 2025-09-08 | 3.14x |
| 2025-09-05 | 3.15x |
| 2025-09-04 | 3.15x |
| 2025-09-03 | 3.07x |
| 2025-09-02 | 3.07x |
| 2025-08-29 | 3.08x |
| 2025-08-28 | 3.09x |
| 2025-08-27 | 2.95x |
| 2025-08-26 | 2.94x |
| 2025-08-25 | 2.96x |
| 2025-08-22 | 3.02x |
| 2025-08-21 | 2.91x |
| 2025-08-20 | 2.96x |
| 2025-08-19 | 2.98x |
| 2025-08-18 | 2.93x |
| 2025-08-15 | 2.96x |
| 2025-08-14 | 2.95x |
| 2025-08-13 | 2.99x |
| 2025-08-12 | 2.92x |
| 2025-08-11 | 2.84x |
| 2025-08-08 | 2.85x |
| 2025-08-07 | 2.84x |
| 2025-08-06 | 2.82x |
| 2025-08-05 | 2.86x |
| 2025-08-04 | 2.86x |
| 2025-08-01 | 2.83x |
| 2025-07-31 | 2.86x |
| 2025-07-30 | 2.93x |
| 2025-07-29 | 2.97x |
| 2025-07-28 | 2.97x |
| 2025-07-25 | 2.98x |
| 2025-07-24 | 2.99x |
| 2025-07-23 | 2.97x |
| 2025-07-22 | 2.89x |
| 2025-07-21 | 2.79x |
| 2025-07-18 | 2.84x |
| 2025-07-17 | 2.89x |
| 2025-07-16 | 2.82x |
| 2025-07-15 | 2.81x |
| 2025-07-14 | 2.98x |
| 2025-07-11 | 3.06x |
| 2025-07-10 | 3.08x |
| 2025-07-09 | 3.01x |
| 2025-07-08 | 3.00x |
| 2025-07-07 | 2.96x |
| 2025-07-03 | 3.01x |
| 2025-07-02 | 2.99x |
| 2025-07-01 | 2.99x |
| 2025-06-30 | 2.93x |
| 2025-06-27 | 2.96x |
| 2025-06-26 | 2.96x |
| 2025-06-25 | 2.95x |
| 2025-06-24 | 2.92x |
| 2025-06-23 | 2.89x |
| 2025-06-20 | 2.87x |
| 2025-06-18 | 2.87x |
| 2025-06-17 | 2.89x |
| 2025-06-16 | 2.96x |
| 2025-06-13 | 2.91x |
| 2025-06-12 | 2.95x |
| 2025-06-11 | 2.97x |
| 2025-06-10 | 2.99x |
| 2025-06-09 | 2.90x |
| 2025-06-06 | 2.88x |
| 2025-06-05 | 2.84x |
| 2025-06-04 | 2.86x |
| 2025-06-03 | 2.81x |
| 2025-06-02 | 2.77x |
| 2025-05-30 | 2.79x |
| 2025-05-29 | 2.89x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell